FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status - a Phase II Study by the GONO Group

被引：1
|
作者：
Fornaro, L. [1 ]
Loupakis, F. [1 ]
Lonardi, S. [2 ]
Masi, G. [1 ]
Salvatore, L. [1 ]
Cremolini, C. [1 ]
Bergamo, F. [2 ]
Cappetta, A. [2 ]
Zagonel, V. [2 ]
Falcone, A. [1 ]
机构：
[1] Univ Pisana, Azienda Osped, UO Oncol Med Univ 2, Pisa, Italy
[2] UOC Oncol Med 1, Ist Oncol Veneto IRCCS, Padua, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71741-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S420 / S420
页数：1
相关论文
共 50 条
  • [21] Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV (FOLFOXIRI) compared with FOLFIRI in metastatic colorectal cancer (MCRC): results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (GONO)
    Falcone, A.
    Brunetti, I. M.
    Benedetti, G.
    Evangelista, W.
    Picone, V.
    Vitello, S.
    Rosso, R.
    Granetto, C.
    Porcile, G.
    Masi, G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 167 - 168
  • [22] Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir)+5FU/LV (IrFL) followed by docetaxel (T)+5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO)
    Loupakis, F.
    Masi, G.
    Bursi, S.
    Picone, V.
    Mentuccia, L.
    Granetto, C.
    Fea, E.
    Murr, R.
    Antonuzzo, A.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] SUNCAP, a phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin.
    Samson, B.
    Latreille, J.
    Nguyen, N. T.
    Sperlich, C.
    Berbiche, D.
    Tournigand, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [24] A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
    Vasile, E.
    Masi, G.
    Fornaro, L.
    Cupini, S.
    Loupakis, F.
    Bursi, S.
    Petrini, I.
    Di Donato, S.
    Brunetti, I. M.
    Ricci, S.
    Antonuzzo, A.
    Chiara, S.
    Amoroso, D.
    Andreuccetti, M.
    Falcone, A.
    BRITISH JOURNAL OF CANCER, 2009, 100 (11) : 1720 - 1724
  • [25] A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), "Mayo regimen", in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC)
    Pozzo, C
    Pyrhönen, S
    Bodrogi, I
    Szanto, J
    Kamica-Mlodkowska, H
    Starkammar, H
    Izso, J
    Hansen, P
    Kjaer, M
    Noël, N
    Gruia, G
    Barone, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S70 - S70
  • [26] A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
    E Vasile
    G Masi
    L Fornaro
    S Cupini
    F Loupakis
    S Bursi
    I Petrini
    S Di Donato
    I M Brunetti
    S Ricci
    A Antonuzzo
    S Chiara
    D Amoroso
    M Andreuccetti
    A Falcone
    British Journal of Cancer, 2009, 100 : 1720 - 1724
  • [27] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [28] Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Greil, R.
    Letocha, H.
    Gamelin, E.
    Thaler, J.
    Hofheinz, R.
    Mineur, L.
    Fernebro, E.
    Karthaus, M.
    Wright, L.
    Koehne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [30] Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study
    Moretto, Roberto
    Battaglin, Francesca
    Antoniotti, Carlotta
    Buggin, Federica
    Delliponti, Laura
    Bergamo, Francesca
    Cremolini, Chiara
    Brunello, Antonella
    Schirripa, Marta
    Menichetti, Alice
    Salvatore, Lisa
    Marsico, Valentina Angela
    Rossini, Daniele
    Rumano', Laura
    Marmorino, Federica
    Falcone, Alfredo
    Zagonel, Vittorina
    Loupakis, Fotios
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345